Michelle Sholzberg

MDCM, MSc, FRCPC

Investigator

Biography

Dr. Michelle Sholzberg received her MDCM and residency training in Internal Medicine at McGill University and she completed additional postgraduate training in Hematology at the University of Toronto. She has also completed a research hemostasis fellowship in Toronto. Dr. Sholzberg has a Master of Science from the University of Toronto in Clinical Epidemiology and Health Care Research. She is a clinical hematologist with a focus on bleeding and is the Medical Director of the Coagulation Laboratory at St. Michael’s Hospital. She is also the Co-Director of the Hematology-Oncology Clinical Research Group and of the Hematology-Immunology Translational Research Theme. Her research interests include inherited and acquired disorders of hemostasis. Currently, she is involved in the study of: prediction tools for perioperative bleeding, the appropriateness of coagulation testing and new treatments for immune thrombocytopenia.

Recent Publications

  1. Sun, HL, Jiwajee, A, Teitel, J, Sholzberg, M. Observational study of efficacy and safety of human cell line-derived recombinant factor VIII in Canadian adults with moderately severe and severe haemophilia A. Haemophilia. 2021; :. doi: 10.1111/hae.14310. PubMed PMID:33866651 .
  2. Parker, ML, Sholzberg, M, Yip, PM, Beriault, DR. The problem with population data for the determination of ferritin lower reference interval limits. Clin Biochem. 2021; :. doi: 10.1016/j.clinbiochem.2021.03.013. PubMed PMID:33781787 .
  3. Arya, S, Wilton, P, Page, D, Boma-Fischer, L, Floros, G, Winikoff, R et al.. "They don't really take my bleeds seriously": Barriers to care for women with inherited bleeding disorders. J Thromb Haemost. 2021; :. doi: 10.1111/jth.15311. PubMed PMID:33774912 .
  4. Talasaz, AH, Sadeghipour, P, Kakavand, H, Aghakouchakzadeh, M, Kordzadeh-Kermani, E, Van Tassell, BW et al.. Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review. J Am Coll Cardiol. 2021;77 (15):1903-1921. doi: 10.1016/j.jacc.2021.02.035. PubMed PMID:33741176 PubMed Central PMC7963001.
  5. Teitel, J, Sholzberg, M, Iorio, A. Extended half-life factor VIII concentrates in adults with hemophilia A: Comparative pharmacokinetics of two products. Res Pract Thromb Haemost. 2021;5 (2):349-355. doi: 10.1002/rth2.12476. PubMed PMID:33733034 PubMed Central PMC7938611.
  6. Sholzberg, M, Tang, GH, Negri, E, Rahhal, H, Kreuziger, LB, Pompilio, CE et al.. Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG - RAPID Trial): A structured summary of a study protocol for a randomised controlled trial. Trials. 2021;22 (1):202. doi: 10.1186/s13063-021-05076-0. PubMed PMID:33691765 PubMed Central PMC7943934.
  7. Tse, B, Lim, G, Sholzberg, M, Pavenski, K. Describing the point prevalence and characteristics of venous thromboembolism in patients with thrombotic thrombocytopenic purpura. J Thromb Haemost. 2020;18 (11):2870-2877. doi: 10.1111/jth.15027. PubMed PMID:33448602 .
  8. Boccia, R, Cooper, N, Ghanima, W, Boxer, MA, Hill, QA, Sholzberg, M et al.. Fostamatinib is an effective second-line therapy in patients with immune thrombocytopenia. Br J Haematol. 2020;190 (6):933-938. doi: 10.1111/bjh.16959. PubMed PMID:33439486 PubMed Central PMC7540289.
  9. Teitel, J, Sholzberg, M. Emergency Management of Hemophilia. J Emerg Med. 2020;59 (4):607-608. doi: 10.1016/j.jemermed.2020.04.063. PubMed PMID:33183681 .
  10. Parker, ML, Storm, S, Sholzberg, M, Yip, PM, Beriault, DR. Revising Ferritin Lower Limits: It's Time to Raise the Bar on Iron Deficiency. J Appl Lab Med. 2021;6 (3):765-773. doi: 10.1093/jalm/jfaa152. PubMed PMID:33179023 .
Search PubMed

Affiliations & Other Activities

  • Staff Physician, Division of Hematology, St. Michael’s Hospital
  • Assistant Professor, Department of Medicine, University of Toronto
X